Form 4: Nautilus Biotechnology Director Farzad Nazem Granted 45,000 Stock Options

Nautilus Biotechnology, Inc. Director Farzad Nazem was granted 45,000 stock options with an exercise price of $0.6951, vesting monthly over one year.

Summary

• Farzad Nazem, a Director of Nautilus Biotechnology, Inc. (NAUT), was granted 45,000 stock options.
• The transaction date for this grant was June 23, 2025.
• The exercise price for these stock options is $0.6951 per share.
• The options are set to expire on June 23, 2035.
• Vesting occurs monthly, with one-twelfth (1/12th) of the shares vesting each month following the grant date, contingent upon Mr. Nazem's continuous status as a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of options aligns the director's interests with shareholders, indicating continued commitment, though it's a routine compensation event.

Positives

• The grant of stock options to Director Farzad Nazem aligns his interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration date, providing a long-term incentive horizon.

Risks

• The vesting of the stock options is subject to Farzad Nazem's continuous status as a 'Service Provider', meaning the options could be forfeited if his service to the company ceases before full vesting.

Future Outlook

The grant of stock options with a monthly vesting schedule over one year indicates an expectation of Farzad Nazem's continued service to Nautilus Biotechnology, aligning his future compensation with the company's performance.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and technology sectors, serving as a key component of executive and director compensation packages designed to align leadership interests with long-term shareholder value creation.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to incentivize long-term commitment and performance.
• The vesting schedule of one-twelfth monthly over a year is a common approach to ensure continued service and retention, comparable to similar equity grants observed in companies like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors, though specific grant sizes and exercise prices vary based on company stage and market capitalization.

Corporate Governance

Related Party Transactions

• The grant of 45,000 stock options to Farzad Nazem, a Director of Nautilus Biotechnology, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from increased alignment of the director's interests with long-term company performance.
• Director (Farzad Nazem): Receives equity-based compensation, incentivizing continued service and contribution to the company's success.

Next Steps

• Farzad Nazem's continued service as a 'Service Provider' to ensure the full vesting of the granted stock options over the next 12 months.

Key Dates

Keywords

Nautilus Biotechnology, NAUT, Form 4, Stock Options, Insider Transaction, Director Compensation, Farzad Nazem, Equity Incentive Plan